Citius Oncology, the oncology‑focused subsidiary of Citius Pharmaceuticals, shipped its first international order of LYMPHIR (denileukin diftitox‑cxdl) to Europe on April 29 2026. The shipment marks the first step in extending LYMPHIR’s availability outside the United States, where the drug was approved by the FDA in August 2024 and launched commercially in December 2025.
LYMPHIR is the first FDA‑approved systemic treatment for relapsed or refractory cutaneous T‑cell lymphoma (CTCL) in more than seven years, addressing a rare disease with an estimated U.S. market exceeding $400 million. The European rollout will be conducted through Named Patient Programs (NPPs) that allow physicians to request the drug for eligible patients while the company navigates local regulatory requirements.
The company will partner with a regional distribution partner to facilitate the NPPs, a strategy that enables early access in markets where full marketing authorization has not yet been obtained. This approach aligns with Citius Oncology’s disciplined, incremental expansion plan and provides a controlled pathway to generate revenue in new territories.
Financially, Citius Pharmaceuticals reported $3.9 million in revenue for the first quarter of fiscal year 2026, driven by initial U.S. sales of LYMPHIR, and a net loss of $8.2 million for the same period. The company had no revenue in the full fiscal year 2025 and reported a net loss of $39.7 million. Cash and cash equivalents stood at $7.7 million as of December 31 2025, underscoring the need for continued capital to support commercialization and expansion.
Leonard Mazur, Chairman and CEO of Citius Oncology, said, "Reaching this milestone underscores our commitment to ensuring that patients in need can access LYMPHIR beyond the United States. Through our distribution partners, we are enabling physicians to request LYMPHIR for appropriate patients via established Named Patient Programs, providing a pathway to treatment where approved alternatives may be limited. Importantly, this progress complements the strong early foundation we are building in the U.S., where we continue to see encouraging adoption across key treatment centers."
The Uniphar agreement, cited by Mazur as the third international distribution partnership, further strengthens the company’s ability to responsibly expand access to LYMPHIR for patients with limited treatment options while laying the groundwork for long‑term global growth. While the first shipment is a milestone, the company’s cash runway and ongoing net losses highlight the importance of achieving commercial traction in the U.S. before scaling internationally.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.